{
    "symbol": "GILD",
    "slug": "gild",
    "display_name": "GILD",
    "category": "stocks",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/asset/gild",
    "lang": "en",
    "as_of": "2026-06-02T00:25:29+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 1,
        "bearish": 0,
        "neutral": 0,
        "explicit": 1,
        "inferred": 0,
        "avg_impact": 5,
        "avg_confidence": 70,
        "last_signal_at": "2026-06-02 00:12:32",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Publication of survivor antibody research progress validates the scientific approach behind remdesivir.",
            "count": 1
        },
        {
            "text": "Renewed investor focus on infectious disease therapies could lift Gilead's antiviral franchise.",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Ebola remains a rare disease with limited commercial market.",
            "count": 1
        },
        {
            "text": "Antibody therapy may fail in clinical trials.",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-06-02 00:12:32",
            "sentiment": "Bullish",
            "impact_score": 5,
            "confidence_score": 70,
            "mention_type": "explicit",
            "timeframe": "mid-term",
            "region": "US",
            "reasoning": "The article highlights efforts to find an Ebola cure from survivor antibodies. Gilead Sciences, developer of remdesivir (originally an Ebola treatment), could benefit if a new cure is discovered or if attention renews interest in its infectious disease pipeline.",
            "article": {
                "title": "Ebola Cure Search: Scientists Trace Survivors' Blood in Remote Mountains",
                "url": "https://finscans.com/news/ebola-cure-search-scientists-trace-survivors-blood-in"
            }
        }
    ]
}